Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease : A prospective, multicentre, observational study
(2024) In Diabetes, obesity & metabolism 26(11). p.4958-4965- Abstract
AIMS: To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
MATERIALS AND METHODS: This was a single-arm, multicentre, prospective study. Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis. Dose adjustments of oral semaglutide were determined by each physician while monitoring efficacy and adverse events.
RESULTS: Significant improvements in body weight, liver enzymes, lipid profile, and glycaemic control were found at 48 weeks compared with baseline values (all p <... (More)
AIMS: To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
MATERIALS AND METHODS: This was a single-arm, multicentre, prospective study. Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis. Dose adjustments of oral semaglutide were determined by each physician while monitoring efficacy and adverse events.
RESULTS: Significant improvements in body weight, liver enzymes, lipid profile, and glycaemic control were found at 48 weeks compared with baseline values (all p < 0.01). Controlled attenuation parameter values significantly decreased from baseline to 48 weeks (p < 0.01). Changes in alanine aminotransferase concentrations (r = 0.37, p < 0.01) and controlled attenuation parameter values (r = 0.44, p < 0.01) were significantly correlated with changes in body weight. Liver fibrosis markers, such as type IV collagen 7S, Wisteria floribunda agglutinin-positive Mac-2-binding protein, fibrosis-4 index, and liver stiffness measurement, significantly decreased from baseline to 48 weeks (all p < 0.01). The most common adverse events were Grades 1-2 transient gastrointestinal symptoms, such as nausea (23 patients, 28.8%), dyspepsia (12, 15.0%) and appetite loss (4, 5.0%).
CONCLUSIONS: Oral semaglutide treatment for T2DM in patients with MASLD leads to an improvement in liver steatosis and injury, surrogate markers of fibrosis, diabetic status, and lipid profile, and reduces body weight.
(Less)
- author
- publishing date
- 2024-11
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Diabetes Mellitus, Type 2/drug therapy, Glucagon-Like Peptides/administration & dosage, Male, Female, Middle Aged, Prospective Studies, Aged, Hypoglycemic Agents/administration & dosage, Administration, Oral, Fatty Liver/drug therapy, Treatment Outcome, Non-alcoholic Fatty Liver Disease/drug therapy, Adult, Blood Glucose/drug effects, Glycated Hemoglobin/analysis
- in
- Diabetes, obesity & metabolism
- volume
- 26
- issue
- 11
- pages
- 4958 - 4965
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:39223865
- scopus:85202938971
- ISSN
- 1462-8902
- DOI
- 10.1111/dom.15898
- language
- English
- LU publication?
- no
- additional info
- © 2024 John Wiley & Sons Ltd.
- id
- 9e8aee93-026e-4e60-8d91-4eaa781c42c8
- date added to LUP
- 2025-01-12 02:05:00
- date last changed
- 2025-07-14 08:17:33
@article{9e8aee93-026e-4e60-8d91-4eaa781c42c8,
abstract = {{<p>AIMS: To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).</p><p>MATERIALS AND METHODS: This was a single-arm, multicentre, prospective study. Among 80 consecutive patients with MASLD and T2DM who newly received oral semaglutide, 70 completed 48-week oral semaglutide treatment as scheduled and were included in an efficacy analysis. Dose adjustments of oral semaglutide were determined by each physician while monitoring efficacy and adverse events.</p><p>RESULTS: Significant improvements in body weight, liver enzymes, lipid profile, and glycaemic control were found at 48 weeks compared with baseline values (all p < 0.01). Controlled attenuation parameter values significantly decreased from baseline to 48 weeks (p < 0.01). Changes in alanine aminotransferase concentrations (r = 0.37, p < 0.01) and controlled attenuation parameter values (r = 0.44, p < 0.01) were significantly correlated with changes in body weight. Liver fibrosis markers, such as type IV collagen 7S, Wisteria floribunda agglutinin-positive Mac-2-binding protein, fibrosis-4 index, and liver stiffness measurement, significantly decreased from baseline to 48 weeks (all p < 0.01). The most common adverse events were Grades 1-2 transient gastrointestinal symptoms, such as nausea (23 patients, 28.8%), dyspepsia (12, 15.0%) and appetite loss (4, 5.0%).</p><p>CONCLUSIONS: Oral semaglutide treatment for T2DM in patients with MASLD leads to an improvement in liver steatosis and injury, surrogate markers of fibrosis, diabetic status, and lipid profile, and reduces body weight.</p>}},
author = {{Arai, Taeang and Atsukawa, Masanori and Tsubota, Akihito and Oikawa, Tsunekazu and Tada, Toshifumi and Matsuura, Kentaro and Ishikawa, Toru and Abe, Hiroshi and Kato, Keizo and Morishita, Asahiro and Tani, Joji and Okubo, Tomomi and Nagao, Mototsugu and Iwabu, Masato and Iwakiri, Katsuhiko}},
issn = {{1462-8902}},
keywords = {{Humans; Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptides/administration & dosage; Male; Female; Middle Aged; Prospective Studies; Aged; Hypoglycemic Agents/administration & dosage; Administration, Oral; Fatty Liver/drug therapy; Treatment Outcome; Non-alcoholic Fatty Liver Disease/drug therapy; Adult; Blood Glucose/drug effects; Glycated Hemoglobin/analysis}},
language = {{eng}},
number = {{11}},
pages = {{4958--4965}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Diabetes, obesity & metabolism}},
title = {{Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease : A prospective, multicentre, observational study}},
url = {{http://dx.doi.org/10.1111/dom.15898}},
doi = {{10.1111/dom.15898}},
volume = {{26}},
year = {{2024}},
}